Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shujie Wang has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Hang Song

    School of Integrated Chinese and Western Medicine Anhui University of Chinese Medicine Hefei China

    2 shared publications
  • Jian Qi

    Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, China

    2 shared publications
  • Xingxing Huo

    Experimental Center of Clinical Research The First Affiliated Hospital of Anhui University of Chinese Medicine Hefei China

    2 shared publications
  • Yongfu Zhu

    Department of Oncology The First Affiliated Hospital of Anhui University of Chinese Medicine Hefei China

    2 shared publications
  • Bo Hong

    Hefei Cancer Hospital of CAS, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences (CAS), Hefei, China

    1 shared publication
  • Hong Wang

    Experimental Center of Clinical Research The First Affiliated Hospital of Anhui University of Chinese Medicine Hefei China

    1 shared publication

Latest Publications

  • Comprehensive Analysis of Chemical and Bioavailable Components of Compound Shougong Powder Using UHPLC–HRMS

    by Hong Wang, Sijie Bian, Yongfu Zhu, Hang Song, Wei Han, Shujie Wang, Qingkai Xue, Xingxing Huo

    Compound Shougong Powder (CSP) is composed of six Chinese herbal medicines and exerts effects in reducing swelling and relieving pain. It is mainly applied in clinical practice as an adjuvant therapy for various malignant tumors; however, its chemical constituents and the material basis of its efficacy have not been fully clarified. This study aimed to clarify the chemical constituents, their migration and distribution in vivo, and the pharmacodynamic material basis and anti‐tumor mechanism of CSP. Ultrahigh‐performance liquid chromatography (UHPLC) combined with high‐resolution mass spectrometry (HRMS) was employed to identify the chemical constituents of CSP and their migration and distribution in mouse serum and tissues; network pharmacology was integrated to explore the potential anti‐tumor mechanism of the stably distributed constituents. A total of 3645 chemical constituents were identified under both positive‐ and negative‐ion modes. Following oral administration, 611 constituents derived from the formulation were detected in mouse serum. In tissues, 1187, 1020, 618, and 401 prototype constituents were identified in the stomach, esophagus, liver, and lungs, respectively. Systematic analysis of all identified constituents revealed 95 that were stably distributed across the original formulation, serum, and the liver, lung, esophagus, and stomach. These 95 constituents stably present in the formula, serum, and target tissues may act synergistically to contribute to the antitumor and analgesic efficacy of CSP. Furthermore, network pharmacology was integrated to explore the potential mechanism of these constituents. A total of 152 overlapping targets between CSP and cancer were identified by Venn diagram analysis. Protein–protein interaction (PPI) network analysis revealed hub genes such as ALB, PTGS2, EGFR, CXCL8, and GSK3B. Gene Ontology (GO) enrichment showed involvement in apoptotic regulation, cell proliferation, and kinase activity, while Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis highlighted key pathways including cancer, PI3K‐Akt, TNF, and MAPK signaling pathways. These findings clarify the chemical constituents and in vivo distribution of CSP, confirm that the 95 stably distributed constituents are the potential pharmacodynamic material basis, and suggest that CSP exerts anti‐tumor effects through a multicomponent, multi‐target, and multi‐pathway regulatory network, providing a basis for further investigation into the pharmacodynamic material foundation of CSP in the treatment of malignant tumors.

  • Open Access

    Integrative analysis of adenosine-related RNA modifications defines molecular subtypes of bladder cancer and identifies CES1 as a driver of tumor progression and immunotherapy resistance

    by Xingxing Huo, Jian Qi, Yongfu Zhu, Hang Song, Wei Han, Shujie Wang

    Background: Adenosine-related RNA modifications, including N6-methyladenosine (m 6 A), N1-methyladenosine (m 1 A), alternative polyadenylation (APA), and adenosine-to-inosine (A-to-I) editing, critically regulate transcriptional programs in cancer. However, their coordinated contribution to bladder cancer biology and response to immunotherapy remains poorly understood. Methods: We systematically characterized four classes of RNA modification “writer” genes in bladder cancer, assessing somatic mutations, copy-number variations, and mRNA expression patterns across seven independent cohorts, including TCGA-BLCA, E-MTAB-4321, and GEO datasets (GSE32894, GSE13507, GSE48276, GSE70691, and GSE69795). Unsupervised consensus clustering identified RNA modification-based molecular subtypes, which were used to construct an RNA modification-based prognostic and immunotherapy response score (RMP_Score). This score was validated across multiple external cohorts, including the IMvigor210 anti-PD-L1 dataset. Differentially expressed genes (DEGs) between subtypes were assessed and integrated through Kaplan-Meier survival analysis and Cox proportional hazards regression to construct the RMP_Score. Bulk and single-cell transcriptomic analyses, complemented by in vitro functional assays, were performed to investigate the role of carboxylesterase 1 (CES1), a key component of the RMP_Score. Tumor microenvironment (TME) composition was quantified using single-sample gene set enrichment analysis (ssGSEA). Results: RNA modification “writer” genes exhibited frequent somatic mutations and copy-number amplifications, which were strongly associated with transcriptional dysregulation and inferior overall survival. Unsupervised clustering revealed two distinct subtypes: a metabolism-enriched cluster associated with favorable prognosis, and an immune- and stroma-enriched cluster characterized by abundant regulatory T-cell infiltration and adverse clinical outcomes. The RMP_Score robustly stratified patient survival across six independent cohorts, correlated with differential sensitivity to inhibitors targeting the JNK/p38, PI3K/mTOR, and WNT pathways, and accurately predicted clinical responses to anti-PD-L1 immunotherapy, with low RMP_Scores demonstrating superior responses. CES1 emerged as a robust predictor of poor survival and immunotherapy resistance, closely associated with tumor progression, extracellular matrix remodeling, and an immunosuppressive, fibroblast-rich TME. Functionally, CES1 silencing significantly attenuated bladder cancer cell viability, invasive capacity, and migratory potential in vitro. Conclusions: These findings established an RNA modification-based framework for molecular classification and risk stratification in bladder cancer, and identified CES1 as a metabolically driven regulator of the TME with potential utility as a prognostic and predictive biomarker for immune checkpoint blockade.

  • Open Access

    CT radiomics-based model for predicting TMB and immunotherapy response in non-small cell lung cancer

    by Jiexiao Wang, Jialiang Wang, Xiang Huang, Yanfei Zhou, Jian Qi, Xiaojun Sun, Jinfu Nie, Zongtao Hu, Shujie Wang, Bo Hong, et al.

    Background: Tumor mutational burden (TMB) is one of the most significant predictive biomarkers of immunotherapy efficacy in non-small cell lung cancer (NSCLC). Radiomics allows high-throughput extraction and analysis of advanced and quantitative medical imaging features. This study develops and validates a radiomic model for predicting TMB level and the response to immunotherapy based on CT features in NSCLC. Method: Pre-operative chest CT images of 127 patients with NSCLC were retrospectively studied. The 3D-Slicer software was used to outline the region of interest and extract features from the CT images. Radiomics prediction model was constructed by LASSO and multiple logistic regression in a training dataset. The model was validated by receiver operating characteristic (ROC) curves and calibration curves using external datasets. Decision curve analysis was used to assess the value of the model for clinical application. Results: A total of 1037 radiomic features were extracted from the CT images of NSCLC patients from TCGA. LASSO regression selected three radiomics features (Flatness, Autocorrelation and Minimum), which were associated with TMB level in NSCLC. A TMB prediction model consisting of 3 radiomic features was constructed by multiple logistic regression. The area under the curve (AUC) value in the TCGA training dataset was 0.816 (95% CI: 0.7109–0.9203) for predicting TMB level in NSCLC. The AUC value in external validation dataset I was 0.775 (95% CI: 0.5528–0.9972) for predicting TMB level in NSCLC, and the AUC value in external validation dataset II was 0.762 (95% CI: 0.5669–0.9569) for predicting the efficacy of immunotherapy in NSCLC. Conclusion: The model based on CT radiomic features helps to achieve cost effective improvement in TMB classification and precise immunotherapy treatment of NSCLC patients.


  • Open Access

    Construction of Ovarian Cancer Prognostic Model Based on the Investigation of Ferroptosis-Related lncRNA

    by Shaoyi Yang, Jie Ji, Meng Wang, Jinfu Nie, Shujie Wang

    (1) Background: Ovarian cancer (OV) has the high mortality rate among gynecological cancers worldwide. Inefficient early diagnosis and prognostic prediction of OV leads to poor survival in most patients. OV is associated with ferroptosis, an iron-dependent form of cell death. Ferroptosis, believed to be regulated by long non-coding RNAs (lncRNAs), may have potential applications in anti-cancer treatments. In this study, we aimed to identify ferroptosis-related lncRNA signatures and develop a novel model for predicting OV prognosis. (2) Methods: We downloaded data from The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression, and Gene Expression Omnibus (GEO) databases. Prognostic lncRNAs were screened by least absolute shrinkage and selection operator (LASSO)-Cox regression analysis, and a prognostic model was constructed. The model’s predictive ability was evaluated by Kaplan–Meier (KM) survival analysis and receiver operating characteristic (ROC) curves. The expression levels of these lncRNAs included in the model were examined in normal and OV cell lines using quantitative reverse transcriptase polymerase chain reaction. (3) Results: We constructed an 18 lncRNA prognostic prediction model for OV based on ferroptosis-related lncRNAs from TCGA patient samples. This model was validated using TCGA and GEO patient samples. KM analysis showed that the prognostic model was able to significantly distinguish between high- and low-risk groups, corresponding to worse and better prognoses. Based on the ROC curves, our model shows stronger prediction precision compared with other traditional clinical factors. Immune cell infiltration, immune checkpoint expression levels, and Tumor Immune Dysfunction and Exclusion analyses are also insightful for OV immunotherapy. (4) Conclusions: The prognostic model constructed in this study has potential for improving our understanding of ferroptosis-related lncRNAs and providing a new tool for prognosis and immune response prediction in patients with OV.